Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sandoz Inc.
Boan Biotech Begins International Phase III Trial Of Denosumab Biosimilars
Having already launched one of its denosumab biosimilar products in China, Boan Biotech has now commenced an international Phase III study to secure approval in Europe, the US and Japan.
Finger On The Pulse: The State Of Biopharma Leadership
In Vivo asked six biopharma figureheads to share their thoughts on the state of leadership in the life sciences space, exploring the qualities of a great leader, how recent years have shaped this role within the industry and the challenges ahead.
Sandoz Faces US Denosumab Lawsuit Ahead Of Key 2025 Patent Expiry
Months after announcing that its GP2411 biosimilar denosumab candidate was accepted for filing by the FDA, Sandoz has been sued for alleged patent infringement by originator Amgen.
Side Step-Wise Development: Sponsors Aren’t Using FDA’s Preferred Approach To Biosimilars
Rather than conduct most analytical characterization and non-clinical studies first, the hallmark of the US FDA approach, biosimilar sponsors are often initiating clinical trials about the same time.
- Generic Drugs
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.